Brief: Regent Pacific Says SenstendTM Approved By NMPA For Premature Ejaculation In China
16/06/2026 16:42
BRIEF-Regent Pacific Says SenstendTM Approved By NMPA For Premature Ejaculation In China June 16 (Reuters) - Regent Pacific Group Ltd 0575.HK:
SENSTENDTM ONE OF ONLY TWO DRUGS APPROVED BY NMPA FOR PREMATURE EJACULATION IN CHINA
EXPECTS TO RECEIVE US$7 MILLION IN 2026 FROM JIANGSU WANBANG BIOPHARMACEUTICAL MILESTONE PAYMENTS
EXPECTS COMMERCIAL MILESTONES AND ROYALTIES UP TO US$25 MILLION IN AGGREGATE UPON ACHIEVEMENT OF ANNUAL NET SALES, OTHERS
Further company coverage: 0575.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Regent Pacific
See all newsBrief: Regent Pacific Says SenstendTM Approved By NMPA For Premature Ejaculation In China
Brief: Regent Pacific Says Deep Longevity To Launch U.S. Expansion In Q1 2026
Brief: Regent Pacific Shall Allot And Issue 63.4 Million Shares At Hk$0.485 Per Share
Brief: Regent Pacific Announces Submission Of Senstend New Drug Application To NMPA In China
Brief: Regent Pacific Enters Manufacturing And Supply Agreement For SENSTEND